Major US Cancer Centre places New System Order

Medical-imaging technology company Polarean which offers an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, has received its latest research unit order for a 9820 Xenon Polariser system from the University of Texas MD Anderson Cancer Center, a major cancer research and teaching hospital.

The new unit will initiate their research programme using hyperpolarised noble gas imaging in oncology, including assessing lung function as consequence of chemotherapy and radiation therapies and providing guidance for improved radiation treatment planning, among other topics.

Richard Hullihen, CEO of Polarean, said: "We are excited to begin our relationship with MD Anderson Cancer Center who have pioneered such a breadth of oncology applications for medical imaging for this patient population, and welcome them to the group of our users researching the use of hyperpolarised 129 Xe in pulmonary function.”